in vivo CART– tag –

Among the many big pharma transactions announced in the last few months, oncology stands out as the area where activity is both dense and conceptually rich. Not only are we seeing large deals in terms of headline value, but they are also...

Last updated: 2025-09-01 JST Lead: The shift from ex vivo to in vivo CAR-T is turning into a full-blown race. Big-ticket M&A, first-patient-dosed milestones, and multiple Phase-1 entries are consolidating the field into two lanes: le...

This article is the first half of the Morningglorysciences Summer Beginner Series Grand Summary. We revisit three major therapeutic modalities—anti-obesity drugs, antibody-drug conjugates (ADCs), and In vivo CAR-T cell therapy—highlighti...

This article is the comprehensive summary of our Morningglorysciences Summer Beginner Series on “In vivo CAR-T.” Previous articles covered the basics, leading researchers and companies, technical challenges, and global partnerships. Here...

Global Strategies Shaping the Future of in vivo CAR-T Development Throughout this series, we have explored the cutting-edge developments of in vivo CAR-T therapy in an accessible way for beginners. In this final installment, we will exam...

Key Figures Shaping the Future of in vivo CAR-T This series aims to provide a clear and accessible overview of the latest advancements in in vivo CAR-T therapies, especially for beginners. In Part 7, we focus on the global researchers, e...

In vivo CAR-T therapy has rapidly emerged as a promising next-generation cancer treatment. However, realizing its full potential requires overcoming several hurdles: targeting only the desired cells, ensuring safety, and maintaining sust...

In previous installments, we've explored the fundamentals of CAR-T, the features of the in vivo model, gene delivery strategies, target antigens, and intracellular signaling. In this fifth edition, we shift our focus to clinical applicat...

In this third installment of our introductory series on in vivo CAR-T, we focus on a vital component for realizing safe and effective therapy: the design of CAR expression. We explore how “smart control” of CAR expression—targeting tumor...

In the first installment of our series, we introduced the revolutionary CAR-T cell therapy through the moving story of Emily Whitehead. This time, we take a deep dive into the underlying technologies that make “in vivo CAR-T” possible. F...

CAR-T cell therapy has emerged as a groundbreaking treatment that specifically targets cancer cells. Among its forms, the “in vivo type” CAR-T—where the therapeutic process happens inside the body—is gaining attention as a next-generatio...